Use of Recombinant Human Erythropoietin and Risk of Severe Retinopathy in Extremely Low-Birth-Weight Infants

被引：20

作者：

Schneider, Jacqueline K. ^{[1
]}

Gardner, Debra K. ^{[2
]}

Cordero, Leandro ^{[3
]}

机构：

[1] Ohio State Univ, Nationwide Childrens Hosp, Dept Pharm Serv, Columbus, OH 43205 USA

[2] Ohio State Univ, Coll Pharm, Columbus, OH 43205 USA

[3] Ohio State Univ, Coll Med, Columbus, OH 43205 USA

来源：

PHARMACOTHERAPY | 2008年 / 28卷 / 11期

关键词：

recombinant human erythropoietin; rHuEPO; anemia of prematurity; extremely low-birth-weight infants; ELBW; retinopathy of prematurity; ROP;

D O I：

10.1592/phco.28.11.1335

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Study Objectives. To evaluate the frequency and severity of retinopathy of prematurity in extremely low-birth-weight (ELBW) infants who received recombinant human erythropoietin (rHuEPO), and to compare the frequency of blood cell transfusions these infants required with a matched control group who did not receive rHuEPO. Design. Retrospective cohort analysis. Setting. Level III neonatal intensive care unit in a large academic medical center. Patients. One hundred thirty-eight ELBW infants who received rHuEPO and 138 ELBW infants who did not (control group) but who were matched by birth weight, gestational age, sex, and year of birth and who survived to the first ophthalmologic examination. Measurements and Main Results. The rHuEPO was started before the 8th day of life in 115 (83%) of the 138 infants. Stages III-V retinopathy of prematurity occurred with similar frequency in both groups of infants (rHuEPO group 19% [26 infants] vs control group 20% 127 infants], p > 0.05). Infants in the rHuEPO group received fewer transfusions on average during their hospitalization compared with those in the Control group (4.2 vs 6.1 transfusions, p < 0.01). Conclusion. Use of rHuEPO for prevention or treatment of anemia of prematurity in ELBW infants does not increase the Frequency of severe retinopathy of prematurity and reduces the number of transfusions.

引用

页码：1335 / 1340

页数：6

共 20 条

[1] Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants [J].

Aher, S. ;

Ohlsson, A. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (03)

[2] Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants:: Results of a randomized, placebo-controlled, multicenter trial [J].

Donato, H ;

Vain, N ;

Rendo, P ;

Vivas, N ;

Prudent, L ;

Larguía, M ;

Digregorio, J ;

Vecchiarelli, C ;

Valverde, R ;

García, C ;

Subotovsky, P ;

Solana, C ;

Gorenstein, A .

PEDIATRICS, 2000, 105 (05) :1066-1072

[3]

GARNER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1130

[4] The incidence and course of retinopathy of prematurity: Findings from the early treatment for retinopathy of prematurity study [J].

Good, WV .

PEDIATRICS, 2005, 116 (01) :15-23

[5]

GROHWARGO S, 2000, NUTR CARE HIGH RISK, P243

[6] Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity [J].

Haiden, N ;

Cardona, F ;

Schwindt, J ;

Berger, A ;

Kuhle, S ;

Homoncik, M ;

Jilma-Stohlawetz, P ;

Pollak, A ;

Jilma, B .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (01) :118-123

[7] Blood transfusion - Iron load and retinopathy of prematurity [J].

Hesse, L ;

Eberl, W ;

Schlaud, M ;

Poets, CF .

EUROPEAN JOURNAL OF PEDIATRICS, 1997, 156 (06) :465-470

[8] Screening examination of premature infants for retinopathy of prematurity [J].

Lichtenstein, SJ ;

Buckley, EG ;

Ellis, GS ;

Kivlin, JD ;

Lueder, GT ;

Ruben, JB ;

Denslow, GT ;

Redmond, MR ;

Repka, MX ;

Alexander, SN ;

Flynn, J ;

Good, W ;

Phelps, DL ;

Reynolds, J ;

Saunders, R .

PEDIATRICS, 2006, 117 (02) :572-576

[9] THE EFFECT OF EPOETIN-BETA (RECOMBINANT-HUMAN-ERYTHROPOIETIN) ON THE NEED FOR TRANSFUSION IN VERY-LOW-BIRTH-WEIGHT INFANTS [J].

MAIER, RF ;

OBLADEN, M ;

SCIGALLA, P ;

LINDERKAMP, O ;

DUC, G ;

HIERONIMI, G ;

HALLIDAY, HL ;

VERSMOLD, HT ;

MORIETTE, G ;

JORCH, G ;

VERELLEN, G ;

SEMMEKROT, BA ;

GRAUEL, EL ;

HOLLAND, BM ;

WARDROP, CAJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (17) :1173-1178

[10] Early treatment with erythropoietin β ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g [J].

Maier, RF ;

Obladen, M ;

Müller-Hansen, I ;

Kattner, E ;

Merz, U ;

Arlettaz, R ;

Groneck, P ;

Hammer, H ;

Kössel, H ;

Verellen, G ;

Stock, GJ ;

Lacaze-Masmonteil, T ;

Claris, O ;

Wagner, M ;

Matis, J ;

Gilberg, F .

JOURNAL OF PEDIATRICS, 2002, 141 (01) :8-15

← 1 2 →